Bruce & Co., Inc. Paratek Pharmaceuticals, Inc. Transaction History

Bruce & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.37 - $2.54 $1,459 - $2,705	-1,065 Reduced 0.07%	1,556,247 $3.95 Million
Q1 2022 May 11, 2022	BUY	$2.94 - $4.77 $335,160 - $543,780	114,000 Added 7.9%	1,557,312 $4.63 Million
Q4 2021 Feb 16, 2022	BUY	$4.07 - $5.3 $407,000 - $530,000	100,000 Added 7.44%	1,443,312 $6.48 Million
Q3 2021 Nov 12, 2021	BUY	$4.7 - $7.24 $846,000 - $1.3 Million	180,000 Added 15.47%	1,343,312 $6.53 Million
Q1 2021 May 17, 2021	BUY	$6.14 - $8.31 $1.44 Million - $1.94 Million	234,000 Added 25.18%	1,163,312 $8.21 Million
Q4 2020 Feb 16, 2021	BUY	$4.58 - $7.14 $229,000 - $357,000	50,000 Added 5.69%	929,312 $5.82 Million
Q3 2020 Nov 13, 2020	BUY	$4.19 - $6.69 $1.31 Million - $2.09 Million	312,760 Added 55.2%	879,312 $4.76 Million
Q2 2020 Aug 14, 2020	BUY	$2.97 - $5.22 $297,000 - $522,000	100,000 Added 21.43%	566,552 $2.96 Million
Q1 2020 May 15, 2020	BUY	$2.67 - $4.97 $534,000 - $994,000	200,000 Added 75.03%	466,552 $1.47 Million
Q2 2019 Aug 14, 2019	BUY	$3.47 - $6.32 $924,935 - $1.68 Million	266,552 New	266,552 $1.06 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Bruce & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on Bruce & Co., Inc. with notifications on news.